Consorci Sanitari Integral
- Address
- Avinguda De Josep Molins 29-41, 08906 L'hospitalet De Llobregat, Spain
Consorci Sanitari Integral - Oncology & Multidisciplinary Research Center
Consorci Sanitari Integral is a comprehensive research center with a strong emphasis on oncology clinical trials, particularly in breast cancer, colorectal cancer, and gastrointestinal malignancies. The center demonstrates extensive expertise in evaluating novel targeted therapies, immunotherapies, and combination treatment approaches across multiple cancer types and stages of disease.
- Breast cancer research including hormone receptor-positive, HER2-positive, and HER2-negative subtypes with focus on CDK4/6 inhibitors, SERD therapy, and antibody-drug conjugates
- Colorectal and gastrointestinal cancers, including metastatic colorectal cancer rechallenge strategies and locally advanced rectal cancer with immunotherapy combinations
- Ophthalmology studies including diabetic macular edema, neovascular age-related macular degeneration, and ocular safety assessments
- Cardiovascular and metabolic disease prevention, autoimmune conditions including IgA nephropathy, ulcerative colitis, and multiple sclerosis
The center participates in pivotal Phase II and Phase III trials evaluating cutting-edge therapies including targeted oral agents, biologics, and immunotherapy combinations. With expertise spanning from adjuvant and neoadjuvant settings to advanced metastatic disease, the center contributes to the development of personalized medicine approaches, including genomic selection strategies using liquid biopsy for treatment optimization in oncology patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorci Sanitari Integral
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension | Novartis Pharma AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 46 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 4 | Unknown | 2021-09-30 | 2025-03-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.